Is ARQT or BEAM more profitable?

ARQT runs the higher net margin — ARQT at 6.15% versus BEAM at -54.75%.

How have ARQT and BEAM total returns compared?

Over the past 5 years, ARQT delivered -0.28% and BEAM delivered -21.41% annualized total return. Past performance doesn't predict future results.

Arcutis Biotherapeutics, Inc. (ARQT) vs Beam Therapeutics Inc. (BEAM)

A side-by-side comparison of Arcutis Biotherapeutics, Inc. and Beam Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ARQT

Arcutis Biotherapeutics, Inc.

$3.09B

$24.69HealthcareDelayed quote: Oct 6, 2026, 12:00 PM EDT

BEAM

Beam Therapeutics Inc.

$2.62B

$25.45HealthcareDelayed quote: Oct 6, 2026, 12:00 PM EDT

Total return — ARQT vs BEAM

growth of $100 · dividends reinvested · last 7y

ARQT +1.7% (+0.2%/yr)BEAM +36.9% (+4.6%/yr)BEAM compounded faster over this window

ARQT BEAM

ARQT vs BEAM: by the numbers

•ARQT is the larger company ($3.09B vs $2.62B market cap).
•ARQT is profitable (6.15% net margin) while BEAM runs a net loss (-54.75%).

Metrics side by side

Valuation

Metric	ARQT	BEAM
P/E ratio	118.39	N/A
Forward P/E	49.65	N/A
P/S ratio	6.65	16.78
P/B ratio	14.00	2.45
EV / EBITDA	85.15	N/A
FCF yield	1.27%	N/A

Profitability

Metric	ARQT	BEAM
Gross margin	91.14%	84.05%
Operating margin	-3.25%	-274.57%
Net margin	6.15%	-54.75%
ROE	12.93%	-8.00%
ROIC	9.95%	-28.96%

Growth (annualized)

Metric	ARQT	BEAM
Revenue CAGR (5Y)	N/A	479.04%
Total return CAGR (5Y)	-0.28%	-21.41%

Frequently asked

Is ARQT or BEAM more profitable?: ARQT runs the higher net margin — ARQT at 6.15% versus BEAM at -54.75%.
How have ARQT and BEAM total returns compared?: Over the past 5 years, ARQT delivered -0.28% and BEAM delivered -21.41% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ARQT analysis Full BEAM analysis Interactive comparison tool

Dig into the metrics

Arcutis Biotherapeutics P/E ratio Arcutis Biotherapeutics ROE Beam Therapeutics ROE Arcutis Biotherapeutics operating margin Beam Therapeutics operating margin Arcutis Biotherapeutics revenue growth Beam Therapeutics revenue growth Arcutis Biotherapeutics free cash flow Beam Therapeutics free cash flow

Arcutis Biotherapeutics & Beam Therapeutics appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.